The notices it replaced
1 notice since 2018, oldest first, each with its awards since FY2014.
- Posted 2018RFA-NS-19-0104 awards
- Posted 2020RFA-NS-21-010This notice, closed · 12 awards
Replaced by RFA-NS-24-019.
Who won it before
Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.
- Past awards
- 16
- 16 new
- Median first-year cost
- $1,895,271
- $30,833,325 in all
- Institutions
- 16
- 16 contact PIs
Awards by fiscal year
0
0
0
0
0
4
0
3
4
4
1
0
0
14151617181920212223242526
Fiscal years 2014 to 2026.
Most frequent institutions
- CENTREXION THERAPEUTICS CORPORATION1
- CLEVELAND CLINIC LERNER COM-CWRU1
- FZATA, INC.1
- HILLHURST BIOPHARMACEUTICALS, INC.1
- IHP THERAPEUTICS, INC.1
and 11 other institutions
Most frequent study sections
- Special Emphasis Panel (ZNS1 SRB-G (37))3
- Special Emphasis Panel (ZNS1 SRB-G (45))2
- Special Emphasis Panel (ZNS1 SRB-G (51))2
- Special Emphasis Panel (ZNS1 SRB-G (55))2
- Special Emphasis Panel (ZNS1 SRB-H (05))2
and 4 other study sections
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| FY2024 | A novel oral immunotherapy for chronic visceral pain of irritable bowel syndrome1UG3NS135350-01A1 | Feng, HanpingWei, FengYang, Zhiyong | FZATA, INC., MD | First-year cost $2,091,549 | Study section ZNS1 |
| FY2023 | Peripherally-restricted non-addictive cannabinoids for cancer pain treatment1UG3NS128148-01A1 | Cahill, Catherine MSchmidt, Brian LSpigelman, IgorSpokoyny, Alexander MichaelWhitelegge, Julian P | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | First-year cost $3,174,343 | Study section ZNS1 |
| FY2023 | A novel glycan-based selectin and complement inhibitor for at-home disease-modifying rescue of pain crisis in sickle cell disease1UG3NS134781-01 | John Paderi, John Paderi John Paderi | IHP THERAPEUTICS, INC., CA | First-year cost $2,589,070 | Study section ZNS1 |
| FY2023 | Development of positive TMEM97 modulators for treating neuropathic pain1UG3NS131304-01 | Martin, Stephen | NUVONURO INC, TX | First-year cost $1,352,240 | Study section ZNS1 |
| FY2023 | Anesthetic-Eluting Contact Lens for Corneal Pain1UG3NS131518-01 | Ciolino, Joseph B. | SCHEPENS EYE RESEARCH INSTITUTE, MA | First-year cost $1,120,889 | Study section ZNS1 |
| FY2022 | Allosteric Targeting of Cannabinoid CB1 Receptor to Develop Non-Addictive Small Molecule Analgesics1UG3NS128439-01 | Lu, DaiSelley, Dana ETao, Feng | TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR, TX | First-year cost $2,903,097 | Study section ZNS1 |
| FY2022 | Development of Pathology-activated Drugs for Treatment of Neuropathic Pain1UG3NS127251-01A1 | Abell, AndrewGrace, Peter M | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | First-year cost $2,408,109 | Study section ZNS1 |
| FY2022 | Oral N2O Therapy in Treating Acute Vaso-Occlusive Pain in Sickle Cell Disease1UG3NS127943-01 | Belcher, John DGomperts, EdwardSimone, Donald | HILLHURST BIOPHARMACEUTICALS, INC., CA | First-year cost $2,111,258 | Study section ZNS1 |
| FY2022 | A first in class, mechanism-guided, cell-based therapy for complex regional pain syndrome1UG3NS127258-01A1 | Cheng, Jianguo | CLEVELAND CLINIC LERNER COM-CWRU, OH | First-year cost $2,033,135 | Study section ZNS1 |
| FY2021 | Novel, Non-Opioid, Non-Addictive Intrathecal Therapy for the Treatment of Chronic Pain1UG3NS123965-01 | Campbell, James N | CENTREXION THERAPEUTICS CORPORATION, MA | First-year cost $2,050,367 | Study section ZNS1 |
| FY2021 | Disease Modifying Analgesia with CA8 Gene Therapy1UG3NS123964-01 | Levitt, Roy C. | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL | First-year cost $1,516,241 | Study section ZNS1 |
| FY2021 | Development of a CCKBR-targeting scFv as Therapy for Chronic Pain Patients1UG3NS123958-01 | Alles, Sascha RWestlund-High, Karin N. | UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR, NM | First-year cost $999,105 | Study section ZNS1 |
| FY2019 | Novel HCN1-selective small molecule inhibitors for the treatment of neuropathic pain1UG3NS114947-01 · under RFA-NS-19-010 | Goldstein, Peter A | WEILL MEDICAL COLL OF CORNELL UNIV, NY | First-year cost $1,757,406 | Study section ZNS1 |
| FY2019 | Novel mGlu5 negative allosteric modulators as first-in-class non-addictive analgesic therapeutics1UG3NS116218-01 · under RFA-NS-19-010 | Conn, P JeffreyGereau, Robert WLindsley, CraigRook, Jerri Michelle | VANDERBILT UNIVERSITY, TN | First-year cost $1,585,635 | Study section ZNS1 |
| FY2019 | Development of MRGPRX1 positive allosteric modulators as non-addictive therapies for neuropathic pain1UG3NS115718-01 · under RFA-NS-19-010 | Tsukamoto, Takashi | JOHNS HOPKINS UNIVERSITY, MD | First-year cost $1,583,144 | Study section ZNS1 |
| FY2019 | Optimization of non-addictive biologics to target sodium channels involved in pain signaling1UG3NS114956-01 · under RFA-NS-19-010 | Wulff, HeikeYarov-Yarovoy, Vladimir M | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | First-year cost $1,557,737 | Study section ZNS1 |
Newest fiscal year first, then first-year cost.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-16-0.3.5. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.